CJC-1295 vs Kisspeptin-10
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CJC-1295
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.
Full details →Kisspeptin-10
Kisspeptin-10 is the active fragment of kisspeptin, a hormone that plays a crucial role in initiating puberty and regulating reproductive function. It acts upstream of GnRH in the hypothalamic-pituitary-gonadal axis.
Full details →Side-by-Side Comparison
| Aspect | CJC-1295 | Kisspeptin-10 |
|---|---|---|
| Mechanism | CJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly. | Binds to KISS1R receptors in the hypothalamus, stimulating GnRH neurons to release GnRH. This triggers the downstream cascade of LH, FSH, and sex hormone production. |
| Typical Dosage | CJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily. | Research protocols vary widely. Studies have used IV boluses of 1-10mcg/kg or subcutaneous administration. Clinical applications still being developed. |
| Administration | Subcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted. | IV or subcutaneous injection. Has very short half-life requiring frequent administration or continuous infusion for sustained effects. |
| Side Effects | Water retention, tingling in extremities, potential increase in cortisol and prolactin levels. | Limited data. May cause flushing, increased heart rate, and changes in libido. Generally well-tolerated in studies. |
| Best For |